Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1260386 (
GSH
)
38,102
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Delta 12-Prostaglandin (PG) J2 caused porcine aortic endothelial cells to synthesize a 31,000-dalton
heme oxygenase
and a 67,000-dalton protein (p67). Treatment of the cells with buthionine sulfoximine (BSO), an inhibitor of glutathione (
GSH
) synthesis, depleted intracellular
GSH
, and enhanced the induction of
heme oxygenase
and p67 syntheses by delta 12-PGJ2. In contrast, treatment with
GSH
increased the intracellular
GSH
level and reduced the induction. There was a reciprocal relationship between the level of intracellular
GSH
, and that of the induction of
heme oxygenase
and p67 syntheses by delta 12-PGJ2. An increase in the intracellular
GSH
level caused an increase in the ethyl acetate-unextractable form of delta 12-PGJ2 in the cytosol, but suppressed the accumulation of delta 12-PGJ2 in the nuclei. Furthermore,
GSH
strongly inhibited the in vitro binding of delta 12-PGJ2 to isolated nuclei, which is N-ethylmaleimide sensitive. Moreover, the induction of
heme oxygenase
and p67 syntheses by the thiol-reactive agents arsenite and diethylmaleate was also inhibited by
GSH
treatment and enhanced by BSO treatment. These results demonstrate that intracellular
GSH
suppresses delta 12-PGJ2-induced
heme oxygenase
and p67 syntheses by inhibiting the binding of delta 12-PGJ2 to nuclei.
...
PMID:Inhibitory effect of an intracellular glutathione on delta 12-prostaglandin J2-induced protein syntheses in porcine aortic endothelial cells. 141 83
The induction of
heme oxygenase
in rat liver by cobaltous chloride (CoCl2) and Co-protoporphyrin IX is entirely prevented by the administration of alpha-tocopherol and allopurinol. CoCl2 was converted in the liver into Co-protoporphyrin IX before it induced
heme oxygenase
activity. Actinomycin and cycloheximide affected to a similar degree the induction of
heme oxygenase
by both CoCl2 and Co-protoporphyrin IX. Administration of either CoCl2 or Co-protoporphyrin strongly decreased the intrahepatic
GSH
pool, a decrease which was completely prevented by the administration of either alpha-tocopherol or allopurinol. The latter compounds prevented
heme oxygenase
induction as well as the decrease in hepatic
GSH
when administered 2 h before, together with, or 2 h after CoCl2. However, when given 5 h after administration of CoCl2, alpha-tocopherol and allopurinol showed no preventive effect. Similar results were obtained when Co-protoporphyrin IX was used, with the difference that when alpha-tocopherol and allopurinol were given 2 h after administration of the inducer, they showed no protective effect. Phenylhydrazine and diamide also induced
heme oxygenase
activity in rat liver. This inductive effect was preceded by a decrease in the intrahepatic
GSH
pool, which took place several hours before induction of the oxygenase. Administration of alpha-tocopherol and allopurinol prevented induction of the oxygenase but had no effect on the decrease in
GSH
levels. These results suggest that the induction of
heme oxygenase
by phenylhydrazine and the diamide is preceded by an oxidative stress which very likely originates in the depletion of
GSH
. The induction of
heme oxygenase
by hemin was not prevented by administration of alpha-tocopherol or allopurinol. Coprotoporphyrin IX did not affect the pattern of the molecular forms of hepatic biliverdin reductase, at variance with CoCl2, which is known to convert molecular form 1 of the enzyme into molecular form 3.
...
PMID:Heme oxygenase induction by CoCl2, Co-protoporphyrin IX, phenylhydrazine, and diamide: evidence for oxidative stress involvement. 171 66
Ten compounds with a wide variety of structures, which decreased hepatic glutachione (
GSH
) content at an early time period after their administration, simultaneously increased hepatic
heme oxygenase
, ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (SAMDC) activities in rats. The compounds examined were four alpha, beta-unsaturated carbonyl compounds, two prototype substrates for
GSH
transferase(s), one epoxide, two isothiocyanates, and an indicator of hepatic function test. Time course studies with 1-chloro-2,4-dinitrobenzene (CDNB) and 1,2-dichloro-4-nitrobenzene (DCNB), which are prototype substrates for
GSH
transferases, showed that there was an inverse relationship between the early depletion of hepatic
GSH
content and induction of
heme oxygenase
, ODC and SAMDC together with a decrease in cytochrome P-450 content and an increase in putrescine content. Buthionine sulfoximine (BSO), an inhibitor of
GSH
synthesis, also increased
heme oxygenase
and SAMDC activities, but not ODC, and it tended to enhance the induction of the enzymes evoked by diethyl maleate (DEM), phorone and CDNB with the sustained depletion of
GSH
content. In contrast,
GSH
treatment inhibited DEM-, phorone-, and CDNB-mediated induction of these enzymes and the early depletion of
GSH
content. N-Acetylcysteine failed to inhibit DEM- and phorone-mediated induction of these enzymes and the early depletion of
GSH
content, while it inhibited somewhat these changes produced by CDNB. The findings suggest that the early depletion of hepatic
GSH
content is prerequisite for and plays a role in the induction of
heme oxygenase
, ODC and SAMDC.
...
PMID:Possible role of glutathione depletion in the induction of rate-limiting enzymes involved in heme degradation and polyamine biosynthesis in the liver of rats. 209 3
We have examined the toxicity of trans-platinum (trans-diamminedichloroplatinum II) to heme and hemoprotein metabolism in the kidney of glutathione (
GSH
)-depleted rats and compared it with that produced by cis-platinum. Unlike cis-platinum treatment (7.0 mg/kg, i.v.) which caused after 7 days significant increases in cytochromes P450 and b5, and a marked decrease in porphyrin content of the kidney, trans-platinum alone (7 mg/kg, i.v.) did not elicit notable changes in these variables when measured 1 or 7 days after treatment. Also, cis-platinum treatment significantly altered the heme degradation pathway by increasing the activity of
heme oxygenase
and decreasing that of biliverdin reductase; trans-platinum treatment did not elicit a response in these activities. However, when rats were given the inhibitor of
GSH
synthesis, D,L-buthionine-S,R-sulfoximine (BSO), the subsequent administration (2 hr later) of trans-platinum produced, in 1 day, the spectrum of responses that were mediated by cis-platinum after 7 days. In the kidneys of rats treated with BSO plus trans-platinum the concentration of platinum measured only about 50% of that detected in the kidneys of rats treated with trans-platinum alone. In the liver, trans-platinum by itself or in combination with BSO was ineffective in altering the measured variables of heme metabolism. The possibility that similarity between cis-platinum and trans-platinum plus BSO may extend to systems other than heme metabolism, e.g.
GSH
synthesis and degradation, was examined. cis-Platinum caused significant inhibition of both renal gamma-glutamyl synthetase and gamma-glutamyl transpeptidase after 7 days, but not after 1 day. Twenty-four hours after treatment, BSO + trans-platinum caused inhibition of gamma-glutamylcysteine synthetase activity, whereas this activity in animals treated with BSO alone had returned to control values. At this time point, neither oxidized glutathione (GSSG)-reductase nor gamma-glutamyl transpeptidase activity was affected by trans-platinum + BSO treatment. The findings suggest that
GSH
constitutes an important defense mechanism against trans-platinum alteration of heme metabolism and may play a role in cellular accumulation of the drug in an inactive complex. It is proposed that BSO treatment, despite resulting in a diminished intracellular concentration of trans-platinum, allows reaction of the metal complex with target molecules by virtue of its ability to deplete
GSH
.
...
PMID:Promotion of trans-platinum in vivo effects on renal heme and hemoprotein metabolism by D,L-buthionine-S,R-sulfoximine. Possible role of glutathione. 233 13
Diethyl maleate (DEM), a well-known glutathione (
GSH
) depletor, causes a dose-dependent increase in hepatic ornithine decarboxylase (ODC) activity as well as
heme oxygenase
activity in rats. Considering the important role ODC has in polyamine biosynthesis in response to endogenous and exogenous stimuli, further extensive studies on the effect of DEM on ODC in relation to its
GSH
-depleting effect were carried out. Specifically, concomitant with the profound decrease in
GSH
content, the higher dose of DEM (1284 mg/kg) caused a marked increase in ODC activity (about 1000 times that of the control) at 12 hr after its administration. DEM at this dose also caused a marked increase in
heme oxygenase
activity, but the effects on cytochrome P-450 content and aminopyrine demethylase activity were less extensive. The increases in ODC and
heme oxygenase
activities evoked by DEM were almost completely blocked by pretreatment of rats with either actinomycin D or cycloheximide. Parallel to the increase in ODC activity, DEM caused a profound increase in putrescine content in the liver, while the agent reduced spermine content. The administrations of alpha-difluoromethylornithine and 1,3-diaminopropane resulted in the inhibition of DEM-mediated induction of ODC, but not
heme oxygenase
. In contrast, methylglyoxal bis(guanylhydrazone) inhibited the induction of both ODC and
heme oxygenase
evoked by DEM. The DEM-induced ODC exhibited two phases of decay with the prolonged half-lives of 26 and 223 min. Additionally, the elution profile from DEAE-Sepharose CL-6B column chromatography of cytoplasmic fraction from DEM-treated rat liver exhibited two peaks of ODC activity. These findings add new insight into the biochemical effect of DEM on hepatic polyamine metabolism in addition to its
GSH
-depleting effect.
...
PMID:Effect of diethyl maleate on hepatic ornithine decarboxylase. 334 Oct 33
Concomitant with the depletion of glutathione content, phorone (250 mg/kg, ip.) produced a marked increase in
heme oxygenase
activity, biphasic effect on delta-aminolevulinic acid synthetase activity, and slight decreases in cytochrome P-450 content and aminopyrine demethylase activity in the liver of rats. The increase in
heme oxygenase
activity evoked by phorone was almost completely blocked by pretreatment of rats with actinomycin D and cycloheximide. Phorone was able to produce the changes in these parameters in a dose-dependent manner. Buthionine sulfoximine, a
GSH
depletor by inhibition of biosynthesis, failed to affect these hepatic parameters.
...
PMID:Effects of phorone (diisopropylidene acetone), a glutathione (GSH) depletor, on hepatic enzymes involved in drug and heme metabolism in rats: evidence that phorone is a potent inducer of heme oxygenase. 359 50
Adult male rats received cobaltous chloride (250 mumol/kg, sc) at various times (1-72 h) prior to assessment of hepatic
heme oxygenase
activity, bile flow, biliary concentration of bilirubin-glucuronides, and hepatic and biliary glutathione concentrations. Hepatic
heme oxygenase
activity increased 360% 24 h after treatment but returned to control levels by 72 h. Total biliary concentrations of the mono- and diglucuronides of bilirubin (BMG and BDG) were increased 47% at 24 h and returned to control levels more slowly than did
heme oxygenase
. Bile flow was not significantly changed at any time. Concentrations of hepatic reduced and oxidized glutathione (
GSH
and GSSG) tended to increase after cobalt, but changes were not statistically significant. Biliary
GSH
and GSSG increased 1 h after cobalt treatment and were twice control values 3 h after treatment. These biliary glutathione concentrations declined to the control range by 6 h. These results demonstrate that increased liver
heme oxygenase
activity following cobalt treatment may be associated with elevated biliary excretion of bilirubin glucuronides. However, changes that occurred in biliary excretion of glutathione in response to cobalt treatment were not accompanied by parallel changes in hepatic glutathione levels.
...
PMID:Effect of cobalt on biliary excretion of bilirubin and glutathione. 384 May 33
A single, intraperitoneal injection of diethyldithiocarbamate (DDTC) to adult, male Sprague-Dawley rats decreased hepatic cytochrome P-450 (P-450) concentrations. This effect was dose-dependent over a range of 250 to 750 mg/kg and most prominent 24-36 hr after dosing. Depletion of hepatic glutathione (
GSH
) by diethylmaleate (DEM) administration significantly decreased P-450 8 hr after concurrent treatment with DDTC at a dose which given alone had little effect on P-450 concentrations. When hepatic microsomes were incubated with DDTC in the presence of NADPH, P-450 was converted to cytochrome P-420 (P-420). Similar incubations employing [35S]DDTC demonstrated strict NADPH-dependent binding of labeled sulfur to microsomal membranes, suggesting that diminished P-450 concentrations are related to the metabolic activation of DDTC. Addition of reduced
GSH
to incubation mixtures blocked the binding of 35S to microsomal membranes, as well as conversion of P-450 to P-420. DDTC inhibited NADPH-ADP3+ mediated peroxidation of microsomal lipids in vitro, suggesting that the effect of DDTC on P-450 does not result from stimulation of lipid peroxidation, but may be influenced by the levels of hepatic
GSH
. DDTC treatment 1 hr after P-450 was pulse labeled by an intravenous injection of [3H]delta-aminolevulinic acid resulted in a 2-fold increase in the rate of loss of radioactivity associated with membrane-bound P-450 heme during the next 20 hr. Within this time interval, hepatic
heme oxygenase
(HO) activity increased and at 8 hr after dosing was 7-fold greater than control values in the livers, but was unchanged in the kidneys and spleens of DDTC-treated animals. An elevation of hepatic delta-aminolevulinic acid synthetase (delta-ALAS) activity occurred at 8 and 24 hr after DDTC treatment. Since this enzyme is rate limiting in the biosynthesis of heme, its increased activity may represent a compensatory response to offset the DDTC-mediated loss of P-450 heme.
...
PMID:Mechanisms of diethyldithiocarbamate-induced loss of cytochrome P-450 from rat liver. 631 Dec 17
Concentrations of reduced glutathione (
GSH
) and oxidized glutathione (GSSG) and 4 trace metals (Ni, Cu, Mn, Zn) were measured in livers from rats treated with sodium diethyldithiocarbamate (DDC, 0.67 or 1.33 mmol/kg, i.m.) and NiCl2 (0.25 or 0.50 mmol/kg, s.c.), singly or in combination. In rats treated with DDC or NiCl2, singly, hepatic
GSH
was diminished at 4 h and returned to control levels (or slightly above) at 17 h. In rats that received DDC plus NiCl2, hepatic
GSH
was not diminished at 4 h after increased 1.4-1.8-fold at 17 h. Hepatic GSSG was diminished at 4 h after NiCl2 treatment and returned to control values at 17 h; hepatic GSSG did not differ from control values at 4 h or 17 h after treatment with DDC, alone or combined with NiCl2. Hepatic Ni was below the detection limit (approximately 20 nmol/g) in control and DDC-treated rats; hepatic Ni was increased to 53 +/- 26 (S.D.) nmol/g at 17 h after treatment with NiCl2 alone, and was increased 6-fold (308 +/- 63 nmol/g) in rats that received Ni plus DDC. Under the same conditions, hepatic Zn was increased 33% or 41%, respectively, in rats that received NiCl2 or DDC, singly, and was not further increased by combined treatment; hepatic Cu and Mn concentrations were unaffected by NiCl2 or DDC, singly, but were diminished in rats that received NiCl2 and DDC. This study suggests: (a) that increased hepatic uptake of Ni is largely responsible for the synergistic induction of
heme oxygenase
activity in rats treated with NiCl2 and DDC; and (b) that increased hepatic uptake of Zn contributes to the induction of hepatic metallothionein by NiCl2 and DDC.
...
PMID:Effects of diethyldithiocarbamate and nickel chloride on glutathione and trace metal concentrations in rat liver. 633 Sep 38
It is apparent that hepatic
GSH
may function in drug metabolism not only as a substrate for conjugation but also in regulation of cytochrome P-450 activity. The remarkable aspect of the latter activity is its specificity. Loss of hepatic
GSH
depresses N-demethylation of DAB while ring hydroxylation is unaffected. On the other hand, the effect is to some degree nonspecific in that control as well as PB- or MC-induced N-demethylation is inhibited. Thus the response may not simply be specific to one isozyme of cytochrome P-450 but may be associated with one aspect of the enzymic activity of several cytochrome P-450 isozymes (i.e., N-demethylation). We have postulated that sensitivity of this activity to lipid peroxidation underlies the relationship to
GSH
since the tripeptide serves as a major protection against hepatic lipid peroxidation and its consequences. It is as yet not clear as to how or why this particular aspect of P-450 activity is more sensitive to lipid peroxidation than are other activities such as ring hydroxylation. Ongoing investigations include attempts to identify the cytochrome P-450 isozyme(s) which inhibit this response to
GSH
depletion.
GSH
-lipid peroxidation relationships have already been reported with isolated hepatocytes, and there may be a possible connection between this and the relative instability of cytochrome P-450 in cultured hepatocytes. Another factor which may be involved is
heme oxygenase
activity, which is markedly induced in the liver after
GSH
depletion, after cobalt administration (which also depresses cytochrome P-450 activity), and during incubation of isolated hepatocytes. This enzyme catalyzes the rate-limiting step in heme breakdown and may contribute to the loss of cytochrome P-450 activity associated with
GSH
depletion.
...
PMID:Glutathione and hepatic mixed-function oxidase activity. 641 2
1
2
3
4
5
6
7
8
9
10
Next >>